Business
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
BERKELEY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical
About this update from Caribou Biosciences, Inc.
[{"type":"text","content":"BERKELEY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that a trial-in-progress abstract for the Company’s ongoing ANTLER Phase 1 clinical trial evaluating CB-010 for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) has been accepted as a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting, being held in New Orleans, Louisiana, December 10-13, 2022. The poster will provide details on the ANTLER clinical trial design and objectives. Details of the poster presentation are as follows: Title: A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)Presenter: Susan O’Brien, M.D., professor, Division of Hematology/Oncology and associate director for clinical science, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA Session Name: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster IIISession Date: Monday, December 12, 2022Presentation Time: 6:00 pm - 8:00 pm CSTLocation: Ernest N. Morial Convention Center, Hall D Abstract number: 4257 The poster presentation will be available for registered attendees on the ASH website and on Caribou’s website Monday, December 12, 2022 at 9:00 am CT. About CB-010CB-010 is the lead product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1 trial. CB-010 is an allogeneic anti-CD19 CAR-T cell therapy engineered using Cas9 CRISPR hybrid RNA-DNA (chRDNA) technology to insert a CD19-specific CAR into the TRAC gene and knock out PD-1 to boost the persistence of antitumor activity. CB-010 is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout. Additional information on the ANTLER trial can be found at https://clinicaltrials.gov using identifier NCT04637763. About Caribou’s Novel Next-Generation CRISPR PlatformCRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Cla...